SOD1 and amyotrophic lateral sclerosis: In order to improve the potential of clemastine in ameliorating ALS disease progression, we performed two different treatments with a high dose of clemastine (50 mg/kg) in SOD1-G93A mice, both starting at postnatal day 40 (PND) but ending at either PND 120 (short treatment) or the end stage of the disease (long treatment) (Fig. 1a).